Meanwhile, Asn has been associated with the release of GLP-1 (glucagon-like peptide-1), a mechanism that has been proposed as a potential reducer of the accumulation of Aβ and its cytotoxic effects in an AD model [63], as well as a controller of insulin resistance, neuroinflammation, neurogenesis, neurite growth in the brain, and memory protection [64]. This evidence concerns the gene INS and Alzheimer disease.